Navigation Links
Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine

ROCKVILLE, Md., Feb. 23 /PRNewswire/ -- Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The three-year award totaling approximately $3 million will support collaborative research by investigators at Sanaria and Columbia University. This new funding extends previous NIAID supported efforts at Sanaria and Columbia to develop genetically modified strains of the human malaria parasite Plasmodium falciparum that are unable to cause disease, yet stimulate protective immunity when administered as a live, whole parasite malaria vaccine. "There is considerable excitement about whole parasite malaria vaccines, and research towards developing genetically modified strains for such vaccines is at the cutting edge of this field," states Dr. Christian Loucq, Director of the PATH Malaria Vaccine Initiative.

Sporozoite stage parasites that have been weakened (attenuated) by exposure to radiation confer high-level protection against malaria when introduced by the bite of infected mosquitoes. The attenuated parasites invade host tissues, but cannot complete differentiation and therefore do not replicate or cause disease. Sanaria has developed technologies and built a facility to manufacture a radiation attenuated sporozoite vaccine that can be administered by injection and has met FDA regulatory standards for initial clinical evaluation.  This vaccine candidate, the SanariaTM PfSPZ Vaccine, is now being assessed in clinical trials. According to Dr. Stephen L. Hoffman, Sanaria's founder and chief scientist, "Sanaria is uniquely positioned at this time to expand the pipeline of candidate sporozoite vaccines to include vaccines based on precisely gene-altered parasites that are highly potent in inducing protective immunity against malaria and are unable to cause disease."

"Sanaria's proven ability to manufacture whole sporozoite vaccines in compliance with FDA standards means that promising new strains of the malaria parasite that are being developed in our research laboratory can be efficiently translated into prototype candidate vaccines suitable for testing in the clinic," says Dr. David Fidock of Columbia University. Dr. Robert Sauerwein of the Radboud University Nijmegen Medical Centre, whose laboratory in collaboration with Sanaria has generated several genetically attenuated strains of Plasmodium falciparum concurs, stating, "This is a very exciting opportunity to make significant strides that will facilitate translation from the laboratory to clinical studies of a vialed, genetically attenuated, sporozoite vaccine inoculated by needle and syringe."  

About Sanaria Inc.

Sanaria Inc. was founded in 2003.  The company's primary mission is to develop and commercialize attenuated whole-parasite malaria vaccines that confer high-level, long-lasting protection against Plasmodium falciparum, the parasite responsible for most of the malaria-associated severe illness and death worldwide. Sanaria's radiation attenuated sporozoite vaccine, SanariaTM PfSPZ Vaccine, entered clinical trials in 2009. Sanaria's corporate headquarters, administrative, research, development, and manufacturing operations are located in Rockville, Maryland. The company's Web site is

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements.

For further information contact:
Media- Adam Richman 301.770.3222, Investors- Robert Thompson 240.403.2750

SOURCE Sanaria Inc.

Back to top



SOURCE Sanaria Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
2. Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
3. UH Superconductivity Center Receives Texas Emerging Technology Fund Award
4. EUCODIS Bioscience Receives EUR 2 Million Cash Injection to Enlarge Product Portfolio and Develop International Markets
5. UC Riverside graphene specialist Jeanie Lau receives national honor at White House
6. Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy
7. Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
8. BioCrysts Partner Shionogi Receives Marketing & Manufacturing Approval For Peramivir in Japan
9. Fibrocell Science, Inc. Receives FDA Complete Response Letter Regarding azficel-T for Wrinkles
10. Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreichs Ataxia Preclinical Development Program
11. Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary ... in their initial angel funding process. Now, they are paying it forward to ... early stage investments in the microbiome space. In this, they join other ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... TEL AVIV, Israel , Nov. 24, 2015  Tikcro Technologies Ltd. ... be held on December 29, 2015 at 11:00 a.m. Israel ... & Co., Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... , election of Eric Paneth and Izhak Tamir ... and Rami Skaliter as external directors; , approval of an ...
Breaking Biology Technology:
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... BOSTON , Oct. 29, 2015  Connected health ... phenomena driving the explosion of technology-enabled health and wellness, ... his new book, The Internet of Healthy ... apps, sensors or smartphones even existed, Dr. Kvedar, vice ... model of health care delivery, moving care from the ...
(Date:10/27/2015)... YORK , Oct. 27, 2015 In ... major issues of concern for various industry verticals such ... is due to the growing demand for secure & ... in various ,sectors, such as hacking of bank accounts, ... for electronic equipment such as PC,s, laptops, and smartphones ...
Breaking Biology News(10 mins):